MediWound announced the U.S. Food and Drug Administration (FDA) has accepted for review its recently submitted Biologics License Application (BLA) for NexoBrid? for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness..
MediWound has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid? for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.